MX2022004912A - Novedoso compuesto de anillo condensado sustituido. - Google Patents

Novedoso compuesto de anillo condensado sustituido.

Info

Publication number
MX2022004912A
MX2022004912A MX2022004912A MX2022004912A MX2022004912A MX 2022004912 A MX2022004912 A MX 2022004912A MX 2022004912 A MX2022004912 A MX 2022004912A MX 2022004912 A MX2022004912 A MX 2022004912A MX 2022004912 A MX2022004912 A MX 2022004912A
Authority
MX
Mexico
Prior art keywords
provides
condensed ring
ring compound
novel substituted
compound
Prior art date
Application number
MX2022004912A
Other languages
English (en)
Inventor
Sachiko Koike
Takayuki Fukaya
Shunichiro UESUGI
Yohei Ikuma
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2022004912A publication Critical patent/MX2022004912A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto novedoso que tiene un excelente efecto inhibidor de ß-lactamasa; la presente invención proporciona: un compuesto que tiene un excelente efecto inhibidor de ß-lactamasa y está representado por la fórmula (1a), (1b) u (11); o una sal farmacéuticamente aceptable del mismo; este compuesto proporciona un agente profiláctico o terapéutico efectivo para infecciones bacterianas cuando se utiliza en combinación con fármacos a base de ß-lactama o se utiliza como un solo agente; la presente invención proporciona también un agente profiláctico o terapéutico efectivo para tratar varias enfermedades, al utilizarse en combinación con los fármacos a base de ß-lactama.
MX2022004912A 2019-10-25 2020-10-23 Novedoso compuesto de anillo condensado sustituido. MX2022004912A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019194753 2019-10-25
PCT/JP2020/039897 WO2021079984A1 (ja) 2019-10-25 2020-10-23 新規置換縮環型化合物

Publications (1)

Publication Number Publication Date
MX2022004912A true MX2022004912A (es) 2022-08-25

Family

ID=75619318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004912A MX2022004912A (es) 2019-10-25 2020-10-23 Novedoso compuesto de anillo condensado sustituido.

Country Status (10)

Country Link
US (1) US20230038124A1 (es)
EP (1) EP4049680A4 (es)
JP (1) JPWO2021079984A1 (es)
KR (1) KR20220088736A (es)
CN (1) CN114929715A (es)
AU (1) AU2020371404A1 (es)
CA (1) CA3155559A1 (es)
MX (1) MX2022004912A (es)
TW (1) TW202130635A (es)
WO (1) WO2021079984A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022371538A1 (en) * 2021-10-19 2024-05-16 Shanghai Jemincare Pharmaceutical Co., Ltd. Tricyclic boronic acid derivative, and preparation method therefor and application thereof
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101975233B1 (ko) * 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
BR112014002845A2 (pt) * 2011-08-19 2017-02-21 Glaxo Group Ltd “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
EP2928898B1 (en) 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
EP3882252A1 (en) 2014-06-11 2021-09-22 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016149393A1 (en) * 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112018077015B1 (pt) 2016-06-30 2022-05-03 Qpex Biopharma, Inc Derivados de ácido borônico e usos terapêuticos dos mesmos
WO2018199291A1 (ja) 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
WO2019009370A1 (ja) 2017-07-06 2019-01-10 大日本住友製薬株式会社 アミド誘導体
WO2019009369A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 イミン誘導体
AU2019259818B2 (en) * 2018-04-27 2023-06-01 Sumitomo Pharma Co., Ltd. Oxo-substituted compound

Also Published As

Publication number Publication date
EP4049680A4 (en) 2024-01-10
KR20220088736A (ko) 2022-06-28
US20230038124A1 (en) 2023-02-09
WO2021079984A1 (ja) 2021-04-29
TW202130635A (zh) 2021-08-16
CN114929715A (zh) 2022-08-19
AU2020371404A1 (en) 2022-05-19
CA3155559A1 (en) 2021-04-29
EP4049680A1 (en) 2022-08-31
JPWO2021079984A1 (es) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
MX2020002033A (es) Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2020011873A (es) Nuevos derivados de quinolina.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2020000576A (es) Compuestos quimicos.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
PH12020551772A1 (en) Oxo-substituted compound
MX2022004912A (es) Novedoso compuesto de anillo condensado sustituido.
MX2021012105A (es) Compuestos de pirrol.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
ZA202204442B (en) Salt forms of a complement component c5a receptor
MX2019006768A (es) Peptidos antimicrobianos.
SG11201907945YA (en) Azetidine derivative
MX2021007258A (es) Composiciones de esparsentan amorfas.
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EA202190316A1 (ru) Конденсированное производное лактама
MX2021003485A (es) Derivados de indano para uso en el tratamiento de infeccion bacteriana.
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect